Key result
TEE-guided PFO closure achieves ~100% success and is linked to migraine relief at 6 months.
Why the study?
PFO closure is typically guided by fluoroscopy with both guidewire and sheath passing through the defect; this study evaluated the feasibility and safety of a fluoroscopy-free, sole TEE-guided approach where only the sheath crosses the PFO.
Does TEE-guided percutaneous PFO closure without fluoroscopy achieve successful occluder release in adult patients with PFO?
Observational (n=117)
No
Does TEE-guided percutaneous PFO closure without fluoroscopy achieve successful occluder release in adult patients with PFO?
TEE-guided percutaneous PFO closure without fluoroscopy is a feasible and safe procedure with a 100% success rate in this cohort, offering significant symptom relief for patients with migraine.
Supports feasibility of fluoroscopy-free TEE-guided PFO closure; leaves open migraine efficacy versus standard approaches in randomized trials.
Background: Percutaneous closure of the patent foramen ovale (PFO) is primarily guided by fluoroscopy in the catheter room, during which procedure both the guidewire and sheath need to pass through the PFO. We performed PFO closure using a transesophageal echocardiography (TEE)-guided approach and only the sheath was passed through the PFO during the procedure. This study aimed to evaluate the feasibility and safety of PFO closure using this technique. Methods: A retrospective observational study was performed. A total of 117 consecutive adult patients underwent percutaneous PFO closure without fluoroscopy, under the sole guidance of TEE in our hospital between December 2018 and December 2021. The data of each patient consisted of preoperative, operative, and postoperative variables collected. The primary outcome is that the occluder was successfully released. The secondary outcomes included perioperative and follow-up transthoracic echocardiography (TTE), Headache impact test-6 (HIT-6) score and clinical symptoms. Results: Transvenous PFO closure under TEE guidance was successful in all cases. The sample consisted of 93 females and 24 males with an average age of 42.3±7.8 years. There were 28 patients with preoperative cerebral infarction [Risk of Paradoxical Embolism (RoPE) score >6 points] and 89 patients with migraine. All patients underwent a preoperative TEE to confirm the presence of PFO, and contrast-enhanced transcranial Doppler (c-TCD) acoustic contrast suggested grades 3 to 4. The average time of surgery for patients (puncture to removal of the sheath) was 32 minutes. Three cases of vagus nerve reflex manifestations during surgery and two cases of transient ventricular arrhythmia all improved after symptomatic treatment. There were no instances of metal allergy, hemolysis, or other acute vascular procedural complications. For all 89 patients with migraine, significant relief or resolution was achieved during the first six-month follow-up (P<0.001). Conclusions: As a monotherapy, percutaneous closure of PFO guided by TEE where only the sheath passes through the PFO during the operation is an effective procedure with a high success rate and a low complication rate.
No takes yet. Share an insight, caveat, or question.
Lei et al. (2023) conducted an observational in Patent foramen ovale (n=117). Transesophageal echocardiography-guided percutaneous PFO closure was evaluated on Successful release of the occluder. Transesophageal echocardiography-guided percutaneous PFO closure achieved a 100% success rate for occluder release and significantly relieved migraine symptoms at 6 months (P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: